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Abstract
Background: Hexokinases (HKs) catalyze the first step in glucose metabolism. Of the three mammalian 100-kDa HK
isoforms, HKI and II can bind to mitochondria and protect against cell death. HKIII does not bind mitochondria, and little is
known about its regulation or cytoprotective effects. We studied the regulation of HKIII at the transcriptional and protein
levels and investigated its role in cellular protection.
Methodology/Principal Findings: We show that like HKII, HKIII expression is regulated by hypoxia, but other factors that
regulate HKII expression have no effect on HKIII levels. This transcriptional regulation is partially dependent on hypoxia-
inducible factor (HIF) signaling. We also demonstrate regulation at the protein level, as mutations in putative N-terminal
substrate binding residues altered C-terminal catalytic activity, suggesting that HKIII activity is governed, in part, by
interactions between these two domains. Overexpression of HKIII reduced oxidant-induced cell death, increased ATP levels,
decreased the production of reactive oxygen species (ROS), and preserved mitochondrial membrane potential. HKIII
overexpression was also associated with higher levels of transcription factors that regulate mitochondrial biogenesis, and
greater total mitochondrial DNA content. Attempts to target HKIII to the mitochondria by replacing its N-terminal 32-amino-
acid sequence with the mitochondrial-targeting sequence of HKII led to protein aggregation, suggesting that this region is
necessary to maintain proper protein folding and solubility.
Conclusions/Significance: These results suggest that HKIII is regulated by hypoxia and there are functional interactions
between its two halves. Furthermore, HKIII exerts protective effects against oxidative stress, perhaps by increasing ATP
levels, reducing oxidant-induced ROS production, preserving mitochondrial membrane potential, and increasing
mitochondrial biogenesis.
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Introduction
Hexokinases (HKs or ATP:D-hexose 6-phosphotransferase [EC
2.7.1.1] in IUB nomenclature) transfer a phosphoryl moiety from
ATP to the 6-hydroxyl of glucose to produce glucose-6-phosphate
(G6P). The glucose phosphorylation reaction carried out by HKs
maintains the concentration gradient necessary for facilitative
glucose transporters (GLUTs) to move glucose into the cell
[1,2,3,4]. There are 4 mammalian hexokinase isozymes: HKI, II,
III, and IV; hexokinase IV is also known as glucokinase (GK). The
molecular weights of HKI, II, and III are approximately 100-kDa,
whereas HKIV has a molecular weight of 50-kDa. The three 100-
kDa HK isozymes have extensive sequence homology and a high
affinity for glucose (Km,1 mM), and are inhibited by the reaction
product G6P; however, differences in tissue expression, cellular
distribution, and regulation suggest that each isozyme has a
distinct metabolic role [5,6,7]. HKI is ubiquitously expressed,
while HKII is primarily expressed in insulin sensitive tissue such as
skeletal and cardiac muscle. HKIII expression is relatively low in
most tissue, with the highest levels reported in lung, kidney, and
liver [7,8,9]. HKIV has a low affinity for glucose, is not inhibited
by G6P, and is expressed mainly in pancreatic B cells and the liver,
where it is believed to function as a ‘glucose sensor’ [8].
The 100-kDa HK isozymes are each composed of two 50-kDa
domains and may have evolved from the genetic duplication and
fusion of an ancestral 50-kDa HK. Early descriptions of these
enzymes proposed that one of the 50-kDa subunits retained
catalytic activity, and the other became the regulatory domain
[7,8]. Only the C-terminal domain of HKI is catalytically active,
but G6P binds to both domains [10,11,12,13,14,15,16]. In HKII,
both domains are catalytically active and sensitive to G6P, and
glucose binding to the N-terminal domain decreases the
concentration of G6P required to regulate the activity of the C-
terminal domain, suggesting that the two halves functionally
interact [17,18]. Like HKI, the catalytic activity of HKIII is
restricted to its C-terminal half [17,19,20].
HKI and HKII also contain a conserved 21-amino-acid
sequence in the N-terminal domain that is predicted to form a
hydrophobic a-helix and enables these proteins to bind to
mitochondria [21,22]. HKIII does not contain the conserved
mitochondrial-binding sequence and is cytoplasmic, although
some investigations report perinuclear binding [23]. One conse-
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prevention of cell death, possibly through interactions with the
voltage-dependent anion channel and inhibition of the mitochon-
drial permeability transition pore, which is a pro-death channel
[24,25]. Overexpression of HKI and HKII in tissue culture
protects against cell death [26], and both the mitochondrial-
binding and glucose-phosphorylation activities of these proteins
are required for their protective effects [27].
The regulation of HKIII and its potential role in cytoprotection
are not well characterized. In this report, we studied the regulation
of HKIII at the transcriptional and protein levels as well as its role
in cellular protection. We show that of the various factors that
regulate HKII, only hypoxia influences HKIII levels through a
HIF-dependent pathway. Mutations in the predicted N-terminal
glucose and G6P binding sites of HKIII decreased activity in the
C-terminus, which suggests that the two halves of HKIII
functionally interact. HKIII also protects against cell death, and
its overexpression increases ATP levels, decreases the oxidant-
induced production of reactive oxygen species (ROS), attenuates
the oxidant-induced reduction in mitochondrial membrane
potential, and increases mitochondrial biogenesis. To better
characterize the importance of mitochondrial binding on the
protective effects of HKs, we attempted to target HKIII to the
mitochondria by replacing the N-terminal 32-amino-acid region of
HKIII with the mitochondrial binding domain of HKII. However,
the resultant chimeric protein aggregated, suggesting that unlike
HKI and HKII, the N-terminal region of HKIII may play a role
in tertiary structure formation and in maintaining protein
solubility.
Methods
Cell culture
N1S1 cells are descended from the Novikoff rat hepatoma cell
line and were a gift from Dr. Andrew Larson (Northwestern); the
cells were maintained as previously described [28]. HEK293
(HEK) cells were obtained from the American Type Culture
Collection (ATCC) and maintained in MEM (Cellgro, Mediatech
Inc.) supplemented with 10% fetal bovine serum (Cellgro,
Mediatech, Inc.); sodium pyruvate; and penn/strep (Gibco,
Invitrogen Corporation).
Cell treatments
For the hypoxia studies, cells were incubated at 1.5% O2 for
24 hours. To stabilize HIF isoforms under normoxic conditions,
cells were incubated with 100 or 300 mM of the prolyl hydroxylase
inhibitor Dimethyloxalyl glycine (DMOG) (Roche) for 24 h before
isolation of mRNA and protein. For evaluation of cAMP or AMP-
activated kinase (AMPK) activation, N1S1 cells were incubated for
24 hours in serum free media with 5 mM forskolin or 1 mM
aminoimidazole carboxamide ribonucleotide (AICAR), respective-
ly (Sigma).
RNA isolation and Western blotting
Total RNA from cells was extracted with RNA STAT (Tel-test
Inc) and reverse transcribed with the TaqMan preamplification
system (Applied Biosystems). Real time polymerase chain reaction
(PCR) was performed using SYBR Green and assayed on the ABI
7500 Detector (Applied Biosystems). Primer sequences for all
targets are listed in Supplemental Table S1. All target mRNA
levels were normalized to an interal housekeeping control (18S or
b2M). For Western blot, cells were lysed and protein samples were
run on an SDS PAGE gel. Western blots were performed using
commercially available antibodys for HKIII and actin (Abcam,
and Santa Cruz respectively).
HKIII and HIF constructs
A plasmid containing HKIII cDNA was kindly provided by
Dr. Graeme Bell (University of Chicago). 59 EcoR1 and 39
BamH1 sites were engineered into the sequence around the
region of interest, then DNA was amplified via PCR and gel
purified. The construct was cloned into the TOPO vector
(Invitrogen), and the DNA sequence was confirmed. Using this
construct as a template, we introduced ATG codons into PCR
primers that initiated protein translation at amino-acid positions
9, 17, 25, and 33, thereby generating truncated versions of the
HKIII protein lacking the first 8, 16, 24, and 32 residues of the
native sequence, respectively. To generate a chimeric HKIII
protein containing the HKII mitochondrial-targeting sequence,
the construct lacking the first 32 amino acids was used as a
template with primers encoding the 21-amino-acid N-terminal
region of HKII. After all DNA sequences were confirmed, the
HKIII fragments were excised via restriction digestion and
subcloned into the pEGFP-N3 vector (Clontech). Constitutively
active HIF-1a and HIF-2a constructs have double proline-to-
alanine point mutations preventing hydroxylation and subsequent
degradation [29]. These constructs were generously donated by
Dr. Mircea Ivan (Indiana University).
Viability assays
The HKIII-GFP fusion construct or the GFP vector was
transfected into HEK using Lipofectamine2000 (Invitrogen).
Expression was confirmed with fluorescent microscopy, and
Western blot analyses of lysates from transfected cells as previously
described [27]. Experiments were performed 36 to 48 hours after
transfection, and cells were cultured overnight in basal MEM
without supplements before each experiment. To induce death,
cells were exposed to exogenous oxidative stress using H2O2 at the
dose and time points indicated. Cell viability was assessed using
propidium iodide exclusion and Annexin V conjugated to Alexa-
350 (Invitrogen) according to the manufacturer’s instructions.
Results were quantified via flow cytometry using the BDFACS
LSR flowcytometer and analyzed using the FlowJo software
program.
ATP assessment
ATP levels were determined using the Cell Titer Glo Assay
from Promega, according to the manufacturer’s recommenda-
tions. Luminescence was recorded with the SpectraMax Gemini
(Molecular Devices), and measurements were normalized to the
total number of viable cells in each sample, as determined by
trypan blue exclusion with cell counts made on a hemocytometer.
ROS measurements
ROS levels were measured using the MitoSOX fluorescent
marker (Invitrogen), which selectively reacts with superoxide.
Briefly, the MitoSox probe (1 mM) was added to cultured cells
10 min prior to the end of the indicated treatment condition. Cells
were then washed with PBS and incubated for 5 min in MEM
containing the Hoechst33342 nuclear marker (Invitrogen). The
media was replaced with fresh MEM and ROS levels were
evaluated via fluorescent microscopy. Images from 5 representa-
tive fields were captured for each individual sample, and
fluorescent intensity in the 510/580 nm spectra was evaluated
using the ImageJ software program (NIH), and normalized to cell
number.
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Mitochondrial membrane potential (Dym), was evaluated using
the fluorescent marker tetramethylrhodamine ethyl ester TMRE
(Sigma) as previously described [27]. Briefly, cells were loaded with
TMRE 10 min prior to the start of the indicated treatment.
Fluorescent microscopy images were taken to demonstrate relative
changes in TMRE intensity. Results were quantified via flow
cytometry as describe above.
Figure 1. Hypoxia regulates HKIII expression in N1S1 cells via HIF signal transduction. (A) HKIII mRNA and protein levels (left and right
panels, respectively) were measured in N1S1 cells cultured under normoxic or hypoxic (1.5% O2) conditions for 24 hours. HKIII levels were significantly
higher after hypoxia treatment. (B) N1S1 cells were cultured under normoxic conditions for 24 hours with or without a HIF stabilizer (DMOG, 100 and
300 mM). HKIII mRNA and protein levels increased significantly after DMOG treatment. (C) HKIII mRNA levels were significantly increased in N1S1 cells
expressing constitutively active (ca) HIF-1a or HIF2a constructs under normoxic conditions, 24 h after transfection. (D) HKIII mRNA levels were
significantly increased after hypoxia in another rat hepatoma cell line (McA-RH 7777), as well as a human myeloid leukemia cell line (HL 60). This
response was not observed in HEK293 cell which had no detectable HKIII expression under normoxic or hypoxic conditions. *P,0.05 v. control; Data
are presented as mean6SEM, N=3–5 for all groups.
doi:10.1371/journal.pone.0013823.g001
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Mitochondrial biogenesis was assessed by determining the
mitochondrial DNA copy number. Total DNA was isolated using
a modification of the spin-column protocol from the DNeasy
Blood and Tissue Kit (Qiagen), then the quantity of the
mitochondrial encoded gene cytochrome c oxidase subunit 1
(CO1) and the quantity of the stable nuclear-encoded gene 18S
ribosomal RNA (rRNA) were measured via PCR. Mitochondrial
DNA copy number was expressed as the ratio of CO1 to
18SrRNA expression.
Hexokinase activity
The QuikChange II Multi-site Directed Mutagenesis Kit
(Stratagene) was used to make point mutations in HKIII
substrate-binding residues. The full-length HKIII protein was
used as the template. HKIII constructs were PCR-amplified from
human genomic DNA and subcloned into pET28a (Novagen).
Proteins were expressed in E. coli (BL21 DE3) and purified with
Ni-NTA affinity chromatography and Superdex 75 (26/60) size-
exclusion chromatography (pre-equilibrated with 10 mM Tris
pH 7.5, 150 mM NaCl, 10 mM MgCl2, and 5 mM DTT).
Proteins were concentrated using an Amicon Ultra centrifugal
filter with purity .95% based on sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) analysis. HK
activity was assessed as described previously [17] by coupling G6P
production with NADP reduction in the presence of G6P
dehydrogenase (G6PDH).
Statistical analysis
Results are presented as mean6SEM. The Student’s t-test was
used to analyze data with unequal variance between each group. A
p-value of less than 0.05 was considered significant.
Results
Hypoxia induces HKIII expression through HIF dependent
signaling
Analysis of the HKIII promoter sequence identified several
putative regulatory elements responsive to cAMP, AMPK, or HIF
signal transduction, which have been shown to regulate HKII
expression [30,31,32]. Treatment of Novikoff N1S1 rat hepatoma
cells, which have measurable baseline levels of HKIII expression,
with the cAMP inducer forskolin or the AMPK activator AICAR
did not significantly change HKIII mRNA expression levels
(Figure S1A and B). However, HKIII expression significantly
increased at the mRNA and protein levels in response to hypoxia
(Figure 1A). Hypoxic regulation of HKIII was also demonstrated
at the mRNA level in other cell types (Figure 1D).
We then studied whether the regulation of HKIII by hypoxia is
through a HIF-dependent pathway. Treatment of N1S1 cells
under normoxic conditions with the prolyl hydroxylase inhibitor
and HIF stabilizer Dimethyloxallyl glycine (DMOG) resulted in a
significant increase in HKIII mRNA and protein levels (Figure 1B).
Overexpression of constitutively active (ca) HIF-1a and 2a
constructs, also resulted in similar increases in HKIII expression
at the mRNA level compared to the vector control (Figure 1C).
These constructs contain double P to A point mutations that
prevent prolyl hydroxylation and subsequent degradation under
normoxic conditions [29]. Overall, the results indicate that
regulation of HKIII expression is partially mediated through
HIF signaling, which does not appear to be isoform specific. HKII
expression served as a positive control for these experiments, and
the data are presented in Figure S2A and B).
N-terminal substrate binding regulates HKIII activity
Glucose binding to the N-terminal domain (N-half) of HKII
influences the regulation of the C-half by G6P [17], demonstrating
HK regulation at the post-translational level. We studied whether
an intramolecular interaction between the two domains also exists
in HKIII. The HKIII sequence was aligned with those of HKI and
HKII to predictwhichresiduesinitsN-andC- terminal halvesbind
glucose, ATP, and G6P. We then generated HKIII constructs with
mutations in these putative binding sites (Figure 2A).
Histidine-tagged wildtype and mutant proteins were expressed
in a bacterial system and purified on a nickel column, and the
Figure 2. Mutations in putative N-terminal substrate-binding
residues of HKIII alter catalytic activity in the C-terminal domain.
(A) Six mutant HKIII proteins were generated, each containing a mutation
in one of the N-terminal or C-terminal binding sites for G6P, ATP, or
glucose. The catalytic activity of each mutant protein was assessed via the
G6P/NADPH-coupling assay. (B) Mutations in the putative N-terminal G6P-
and glucose-binding sites significantly impaired HKIII specific activity.
*P,0.05 vs WT. Vmax =.136.010; .096.009; .126.009; .0986.009 for Wt,
E95A, S102A, and T174A respectively. There was no detectable change in
absorbance for the C-terminal mutant constructs. *P,0.05 v. Wt; Data are
presented as mean6SEM, N$3 replicates for each construct.
doi:10.1371/journal.pone.0013823.g002
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G6P/NADPH-coupling assay. Mutations in the C-terminal
domain abolished glucose phosphorylation, which is consistent
with previous reports indicating that the catalytic activity of HKIII
is restricted to the C-terminal domain (data not shown) [8,19,33].
Mutations in the putative N-terminal glucose- and G6P-binding
sites reduced the specific activity of the protein (Figure 2B), but the
putative N-terminal ATP-binding site mutation did not. Collec-
tively, these results suggest that inhibition of glucose or G6P
binding, but not ATP binding, in the N-terminal domain reduces
the catalytic activity of the C-terminal domain. Thus, there is
functional interaction between the N- and C-halves of HKIII.
HKIII overexpression protects against oxidant-induced
cell death
Previous studies have shown that HKI and II protect cells from
oxidant-induced cell death [27,34]. We next studied the potential
role of HKIII in cytoprotection, using a similar model of H2O2
induced cell death in HEK293 (HEK) cells [27]. Cells were
transfected with plasmids coding for GFP or HKIII-GFP
expression, and overexpression was confirmed via confocal
fluorescent microscopy and Western blot (Figure 3A and B).
Furthermore, overexpression of the HKIII-GFP construct resulted
in a significant increase in total hexokinase activity compared to
GFP (Figure 3C).
Thirty-six to forty-eight hours after transfection, cells were
serum starved overnight in basal MEM media, and then exposed
to oxidative stress using exogenous H2O2. Cell viability was
assessed using propidium iodide exclusion and Annexin V to
evaluate necrotic and apoptotic cell death, respectively. Both
assays demonstrate that survival was higher in cells transfected
with the HKIII-GFP plasmid than in GFP transfected controls
(Figure 4 A–D). These results indicate that HKIII protects against
oxidant-induced cell death.
HKIII overexpression increases ATP levels and reduces
ROS production
Glucose metabolism is necessary to maintain cellular ATP levels
which is vital to cell viability [35]. To evaluate the effect of HKIII
on cellular energy production, we measured ATP levels in HEK
cells transfected with HKIII-GFP or GFP plasmid. Cells were
serum starved overnight in basal MEM media, and then treated
with 500 mM H2O2 before the assessment of ATP levels. Cells
overexpressing HKIII-GFP had significantly higher ATP levels at
baseline and after exposure to H2O2, compared with GFP controls
(Figure 5A).
Increased ROS production can also induce celldeath, and we have
previously shown that the overexpression of HKI or HKII reduces
cellular ROS levels [27]. Here, we evaluated the potential influence
of HKIII on ROS production. Under normal culture conditions,
ROS levels in cells transfected with HKIII-GFP or GFP were not
readily detected using the fluorescent mitochondrial superoxide
indicator MitoSox (Figure 5B); however, ROS production after
exposure to exogenous H2O2 was significantly lower in HKIII-GFP
overexpressing cells compared to GFP controls (Figures 5B and C,
S3A and B). Collectively, these results suggest that the reduction in
celldeathassociated withHKIIIoverexpressioncouldevolvefroman
increase in ATP levels or a decline in ROS production.
Figure 3. Overexpression of HKIII in HEK293 cells. (A) Confocal microscopy images demonstrate successful transfection of HEK293 cells with
the GFP and HKIII-GFP vector plasmids. HKIII-GFP does not appear cytosolic with no observed localization to any subcellular compartment. The cells
were stained with TMRE (red) to identify mitochondria, and nuclei were labeled with Hoechst (blue). (B) Overexpression was confirmed by Western
blots of cell lysates with a GFP antibody. (C) Total hexokinase activity was significantly increased in cells overexpressing HKIII compared to GFP
control.
doi:10.1371/journal.pone.0013823.g003
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membrane potential and mitochondrial biogenesis
The increased energy reserve and reduced ROS levels
observed in stressed cells overexpressing HKIII suggest that
HKIII may have an impact on the mitochondria. Previous
studies have shown that HKI and II attenuated the loss of
mitochondrial membrane potential in cells exposed to oxidative
stress [27]. We next studied the effects of HKIII overexpression
on membrane potential using TMRE as previously described
[27]. Overexpression of HKIII did not impact overall TMRE
fluorescence at baseline; however TMRE fluorescence was
significantly higher in cells overexpressing HKIII-GFP after
exposure to oxidative stress compared to GFP controls
(Figures 6A-E, S4A and B).
Studies have also shown that elevated glucose metabolism is
associated with increased mitochondrial biogenesis [36,37], so we
compared the expression of genes known to play a role in
mitochondrial biogenesis and the overall mitochondrial DNA
content in HEK293 cells transfected with HKIII-GFP or GFP.
Overexpression of HKIII increased mRNA levels of PGC-1a and
the nuclear regulatory factors (NRF) 1 and 2a (Figure 7A), which
regulate the expression of nuclear genes involved in mitochondrial
biogenesis. HKIII overexpression also induced expression of
several genes involved in the TCA cycle, fatty acid transport,
and b-oxidation (Figure 7B). Total mitochondrial DNA content
was also higher in cells that overexpressed HKIII-GFP than in
GFP-overexpressing cells (Figure 7C). Thus, the overexpression of
HKIII appears to increase mitochondrial biogenesis. This process
could also contribute to the cytoprotective effects of HKIII.
Figure 4. Overexpression of HKIII protects against oxidant induced cell death. HEK cells overexpressing HKIII or GFP were treated with
500 mMo fH 2O2, and assayed for cell death using propidium iodide (PI) staining as an indicator of compromised membrane integrity and Annexin V
as a marker of apoptosis. (A) Representative flow output demonstrating a reduction in the number of PI positive cells after treatment with H2O2
(500 mM, 6 h) in samples overexpressing HKIII v GFP. (B) Cell viability was significantly increased in cells overexpressing HKIII compared to GFP after
exposure to 500 mMH 2O2 at the 6 and 12 h time points, as determined by propidium iodide (PI) exclusion. (C) Representative flow output
demonstrating a reduction in the number of cells positive for the apoptotic marker Annexin V after treatment with H2O2 (500 mM, 6 h) in samples
overexpressing HKIII v GFP. (D) HKIII overexpression resulted in decrease in apoptotic cell death after exposure to 500 mMH 2O2 at the 6 and 12 h time
points, as determined by AnnexinV. Cell counts were normalized to counts obtained without H2O2 treatment. *P,0.05 vs GFP. Data are presented as
mean6SEM. N=3–6.
doi:10.1371/journal.pone.0013823.g004
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in cells overexpressing HKIII both at baseline and after treatment with exogenous H2O2 (500 mM, 6 h). Cells were incubated overnight in serum free
basal MEM media, and ATP levels were determined via the Cell Titer Glo assay, with luminescence (RLU) normalized to the number of viable cells.
N=6. (B) HEK293 cells were transfected with HKIII-GFP or GFP, treated with or without 500 mMH 2O2 (3 h), and then ROS levels were measured with a
fluorescent marker of superoxide production (MitoSox, red). Nuclei are labeled with Hoechst (blue), and the GFP overlay for these images is presented
in the supplemental material. (C) HKIII overexpression was associated with significantly lower ROS levels in H2O2-treated cells. (N=3, ROS levels for
each sample represent the average fluorescent intensity from 5 separate fields, each normalized to cell number). *P,0.05 vs GFP. Data are presented
as mean6SEM.
doi:10.1371/journal.pone.0013823.g005
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membrane potential was assessed in HEK cells overexpressing HKIII or GFP after treatment with H2O2, using the fluorescent dye
tetramethylrhodamine ethyl ester TMRE (orange). (A) Fluorescent images taken 3 and 6 h after exposure to 500 mMo fH 2O2 demonstrate a
pronounced reduction in TMRE fluorescence over time in cells overexpressing GFP that was attenuated in (C) cells overexpressing HKIII. TMRE images
are overlayed with the Hoechst nuclear stain (blue) for (B) GFP and (D) HKIII. The fluorescent GFP overlay for each image is presented in the
supplemental material. (E) TMRE levels, quantified by flow cytometry, were significantly higher in cells overexpressing HKIII v GFP control 3 and 6 h
after treatment with 500 mMo fH 2O2. N=3–6. *P,0.05 vs GFP. Data are presented as mean6SEM.
doi:10.1371/journal.pone.0013823.g006
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for proper protein expression
Previous studies have shown that the binding of HKI and HKII
to mitochondria protects against cell death [27]. Thus, we
investigated whether the protective effects of HKIII, which is a
cytoplasmic protein, could be enhanced by replacing its N-terminal
32 amino acids (encoded by exon 1b of HKIII) with the 21-amino-
acid mitochondrial-targeting (Mt) sequence of HKII (encoded by
exon 1 of HKII) (Figure 8A). Overexpression of the chimeric Mt-
HKIII protein (containing the HKII mitochondrial-targeting
sequence in place of the N-terminal 32 amino acids of HKIII) did
not lead to co-localization with the mitochondria, which was
observed with overexpression of HKII (Figure 8B) [27]. In addition,
overexpression of the mitochondrial targeted chimera (Mt-HKIII)
led to the formationof protein aggregates(Figure 8B). To determine
whether aggregation wascaused by the removal of the native HKIII
32amino acid sequence, or by the addition of the mitochondrial-
targeting sequence of HKII, we deleted the native sequence only
(Figure 8A). Overexpression of this truncated construct (Tr-HKIII)
also caused protein aggregation (Figure 8B), suggesting that the N-
terminal 32 amino acids of HKIII are essential for proper folding of
the protein. Consistent with these findings, overexpression of the C-
terminal domain of HKIII formed aggregates, whereas the N-
terminal domain was soluble, and its cytosolic expression was
similar to that of the full-length protein (Figure S5A and B).
In an attempt to identify specific N-terminal HKIII residues
required to maintain solubility, we progressively deleted 8-amino-
acid sequences in this region, and expressed these mutants in
HEK293 cells (Figure S6A). The overexpressed proteins were
soluble; indicating that partial truncation of this N-terminal region
does not result in aggregate formation (Figure S6B). Western blot
demonstrating protein expression in HEK293 cell lysates is shown
for all constructs in Figure S7A. Overall, these results suggest that
the N-terminal 32-amino-acid sequence of HKIII is necessary to
maintain solubility and proper expression of the protein.
Discussion
Three 100-kDa HK isozymes are expressed in mammalian
tissue [7,8,27,38,39]. The regulation, localization, activity, and
cytoprotective capacity of HKI and HKII have been extensively
studied. [10–17,21,22,27]. However, the regulation of HKIII and
its potential cytoprotective role are not well characterized. Here,
we show that: 1) HKIII is regulated by hypoxia through a HIF-
dependent pathway, 2) glucose and G6P binding to the N-terminal
domain regulates the catalytic activity of the C-terminal domain,
3) overexpression of HKIII protects cells from oxidant-induced cell
death, and 4) HKIII overexpression increases cellular ATP levels,
reduces ROS production, preserves mitochondria membrane
potential, and promotes the expression of genes that regulate
mitochondrial biogenesis. The latter results suggest that the
protective effects of HKIII may evolve through a decline in
ROS levels and increases in ATP and mitochondrial biogenesis.
Our results also demonstrate that the 32 amino acids encoded by
exon 1b of HKIII and located at the protein’s N-terminus appear
to be essential for proper folding, because deletion of these residues
led to protein aggregation.
Previous studies have identified distinct differences between the
regulation of HKI and HKII [7,8]. Analysis of the HKI promoter,
as well as the ubiquitous tissue expression of this isoform, indicate
that HKI is constitutively expressed, while HKII expression is
tissue specific and regulated by stimuli such as insulin and hypoxia
[7,30,31,32,39,40]. HKIII is primarily expressed in the lung,
kidney, and liver [7,9,41], and an Oct-1 binding site is necessary
Figure 7. Overexpression of HKIII increases expression of
markers associated with mitochondrial biogenesis and mito-
chondrial DNA content. (A) HKIII overexpression lead to significant
increases in the expression of NRF-1, NRF-2a, and PGC-1a, which
regulate mitochondrial biogenesis. (B) Genes encoding regulatory
elements of the TCA cycle, fatty acid transport, and b-oxidation were
also upregulated after HKIII overexpression. Data represent transcript
levels first normalized to an internal housekeeping control and
presented relative to GFP expression. (C) HEK293 cells were transfected
with HKIII-GFP or GFP; 48 hours later, changes in mitochondrial DNA
content were determined by measuring the levels of the mitochondrial
encoded gene CO1 and the nuclear encoded 18S gene. Overexpression
of HKIII significantly increased the ratio of mitochondrial encoded to
nuclear-encoded DNA. *P,0.05. Data are presented as mean6SEM,
N=3. CO1: cytochrome c oxidase subunit 1; Cpt1-b: Carnitine O-
palmitoyltransferase I, muscle isoform; CS: citrate synthase; MCAD:
Medium-chain acyl-CoA dehydrogenase; NRF: Nuclear Regulatory
Factor 1,2a; PDK4: pyruvate dehydrogenase kinase 4; PGC-1a:
Peroxisome proliferator-activated receptor gamma coactivator-1 alpha.
doi:10.1371/journal.pone.0013823.g007
HK3 Regulation and Protection
PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e13823for basal HKIII expression [9], but little else is known about the
regulation of HKIII activity. Sequence analysis of the HKIII
promoter identified several putative regulatory elements that may
respond to cAMP, AMPK, or HIF signal transduction. Pharma-
cological stimulation with cAMP or AMPK activators (forskolin
and AICAR, respectively) had no measurable effect on HKIII
mRNA expression, but cellular HKIII expression was significantly
increased by hypoxia through a HIF-dependent pathway. These
findings are the first to demonstrate that HKIII expression is
regulated by a specific signaling pathway, and identifies a likely
role for this isozyme in the cellular response to the metabolic
stresses induced by hypoxia. Furthermore, the inducible expres-
sion of HKII and III suggests that these enzymes have a role
in adaptive metabolic responses to changes in the cellular
environment.
Previous reports also indicate that the two domains of HKI and
HKII do not function independently. Here, we demonstrate that
mutation of the glucose- or G6P-binding sites in the N-half of
HKIII impairs catalysis in the C-half. Thus, the activity of HKIII
appears to be governed, in part, by functional interactions between
the two domains. Previous studies on HKI demonstrate a
cooperative effect of glucose binding in the N-half to subsequent
binding in the C-half [42,43]. It is possible that a similar
intramolecular interaction occurs in HKIII, and reduction in N-
half glucose binding results in diminished C-half binding, and an
overall reduction in activity; however, other possibilities cannot be
excluded. We also found that a mutation in the putative N-
terminal G6P binding site reduced HKIII activity. This observa-
tion (i.e., that mutation of an inhibitory site would decrease
enzyme activity) was unexpected and may have been caused by a
structural change that adversely affected glucose binding in the N-
half. Furthermore, mutation of the N-terminal ATP binding site
did not alter the catalytic activity of the enzyme, which suggests
that either the mutated residue was not essential for N-terminal
ATP binding, or ATP binding in the N-half of HKIII does not
regulate the activity of the C-half. Further enzymatic analysis
Figure 8. Removal of the N-terminal 32 amino acids of HKIII causes protein aggregation. (A) Plasmids coding for the expression of the full-
length HKII (HKII); full length HKIII (HKIII), a chimeric protein replacing the 32amino acid N-terminal region of HKIII (encoded by exon 1b) with the
21aa mitochondrial-targeting sequence of HKII (Mt-HKIII), and a truncated version that lacked the N-terminal 32aa region encoded by exon 1b (Tr-
HKIII). Each construct also coded for GFP expression at the C-terminus. (B) Live cell confocal images of HEK cells after transfection with the indicated
constructs. Overexpression of HKII resulted in co-localization with the mitochondria membrane marker TMRE (red). Co-localization was not observed
with overexpression of the HKIII or Mt-HKIII constructs. Overexpression of Mt-HKIII or the truncated HKIII constructed resulted in aggregate formation
(white arrows). Nuclei were labeled with Hoechst (blue).
doi:10.1371/journal.pone.0013823.g008
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HKIII will help clarify the effects of N-terminal substrate binding
on HKIII activity.
The protective effects of HKI and HKII are believed to occur
through changes in the glucose-phosphorylation and mitochon-
drial-binding activity of the enzymes [27]. Since HKIII does not
bind to mitochondria, we proposed that its protective effects are
due to: 1) an increase in glucose phosphorylation, energy
production and mitochondrial biogenesis, and 2) a reduction in
cellular ROS levels. Our results demonstrate that overexpression
of HKIII results in an increase in cellular ATP levels and
mitochondrial biogenesis, and a decrease in oxidant induced ROS
production. Although these results do not demonstrate a cause and
effect relationship between these factors and cell death, they
implicate their possible role in this process.
The binding of HKI and HKII to the mitochondria is
physiologically significant, because it contributes to their cytopro-
tective effects, and dislocation of HKI and HKII to the cytoplasm
is associated with higher rates of cell death [26,27,44]. Mitochon-
drial binding occurs through a 21-amino-acid, N-terminal
sequence encoded by exon 1 of the HKI and HKII genes, which
is predicted to form a hydrophobic alpha-helix that binds to the
outer membrane of the mitochondria. In this study, we
investigated whether the protective effects of HKIII could be
enhanced by replacing the N-terminal 32 amino acids of HKIII
(encoded by exon 1b) with the 21-amino-acid mitochondrial-
targeting sequence of HKII (encoded by exon 1). Our results
indicate that the sequence in HKIII, encoded by exon 1b, is
critical for protein folding, since its deletion or its replacement with
the mitochondrial-targeting sequence of HKII resulted in the
formation of intracellular aggregates. The sequences encoded by
exon 1 are unique to the 100-kDa mammalian HKs and they are
not present in the 50-kDa HKs expressed in yeast and other
organisms. In 100-kDa enzymes, the N-half (encoded by exons 2
through half of exon 10) and the C-half (encoded by exons 10-18)
form the catalytic and regulatory portion of the proteins, while
exon 1 is not part of the duplication process and encodes unique
sequences. We showed that unlike HKI and HKII, this region of
HKIII is needed for proper folding of the protein and that its
deletion makes the enzyme insoluble, leading to aggregate
formation.
In summary, the results reported here are the first to describe
the regulation of HKIII expression and activity and to characterize
the role of HKIII in cytoprotection. HKIII expression is regulated
by hypoxia through a HIF-dependent signal transduction
pathway, and the activity of HKIII is also regulated at the protein
level by the influence of N-terminal substrate binding on C-
terminal catalysis. HKIII overexpression promotes cell survival in
response to oxidative stress, perhaps by increasing cellular ATP
levels, decreasing ROS production, and promoting mitochondrial
biogenesis, and the sequence encoded by exon 1b of HKIII is
critical for proper protein folding, whereas the corresponding
sequences in HKI and HKII function as mitochondrial-targeting
signals. Collectively, these observations provide insights into the
specific role of the HKIII isozyme in cell metabolism and function.
Supporting Information
Table S1 Primer Sequences used for PCR Amplification
Found at: doi:10.1371/journal.pone.0013823.s001 (0.60 MB TIF)
Figure S1 HKIII levels do not change in N1S1 cells after cAMP
or AMPK activation. HKIII mRNA expression was measured in
N1S1 cells cultured for 24 hours with or without (A) 5 microM
forskolin (an inducer of cAMP production) or (B) 1 mM AICAR
(an activator of AMPK). HKIII mRNA levels in treated and
untreated cells were similar. Data are presented as mean+SEM,
N=3 for all groups.
Found at: doi:10.1371/journal.pone.0013823.s002 (0.52 MB
TIF)
Figure S2 Hypoxia regulates HKII expression in N1S1 cells. (A)
HKII mRNA levels were measured in N1S1 cells cultured under
normoxic or hypoxic (1.5% O2) conditions for 24 hours. HKII
levels were significantly increased after hypoxia treatment. (B)
N1S1 cells were cultured under normoxic conditions for 24 hours
with or without a HIF stabilizer (DMOG, 100 and 300 mM). HKII
mRNA levels increased significantly after DMOG treatment. (C)
Comparative mRNA expression levels of the HKII and HKIII
isoforms in N1S1 cells cultured under normoxic or hypoxic (1.5%
O2) conditions for 24 hours, demonstrating the higher levels of
HKII expression in this cell type. *P,0.05 v. control; Data are
presented as mean6SEM, N=3–5 for all groups.
Found at: doi:10.1371/journal.pone.0013823.s003 (0.45 MB TIF)
Figure S3 Overexpression of GFP and HKIII-GFP in HEK
cells labeled with Mitosox. (A) GFP fluorescent overlay for the
HEK cell images displayed in figure 5B, demonstrating the
overexpression of the GFP and HKIII-GFP constructs in cells
treated with or without 500 mM H2O2 (3 h), and then incubated
with (MitoSox). Cell nuclei are labeled with Hoechst (blue).
Found at: doi:10.1371/journal.pone.0013823.s004 (2.61 MB TIF)
Figure S4 Overexpression of GFP and HKIII-GFP in HEK
cells labeled with TMRE. (A) GFP fluorescent overlay for the
HEK cell images displayed in figure 6 A-D, demonstrating the
overexpression of the GFP (top panels) and HKIII-GFP (bottom
panels) constructs in cells loaded with TMRE(orange) prior to the
treatment condition indicated. Cell nuclei are labeled with
Hoechst (blue).
Found at: doi:10.1371/journal.pone.0013823.s005 (5.19 MB TIF)
Figure S5 Overexpression of the N and C-terminal domains of
HKIII in HEK293 cells. (A) Plasmid constructs coding for the
expression of the N and C-terminal domains of HKIII. Each
construct also coded for GFP expression at the C-terminus. (B)
Live cell confocal images of HEK cells after transfection with the
indicated constructs reveals soluble expression of the N-terminal
half of HKIII (NHKIII) similar to the full length HKIII construct,
while overexpression of the C-terminal domain resulted in
aggregate formation. The cells were incubated with TMRE (red)
to identify mitochondria, and nuclei were labeled with Hoechst
(blue).
Found at: doi:10.1371/journal.pone.0013823.s006 (2.89 MB TIF)
Figure S6 Progressive deletion of 8-amino-acid segments from
the N-terminus of HKIII do not cause protein aggregation. (A)
Plasmids expressing truncated versions of HKIII that lacked the
first 8 (HKIII-8), 16 (HKIII-16), or 24 (HKIII-24) amino acids of
the N-terminal sequence encoded by exon 1b were constructed
and expressed in HEK293 cells; each construct also coded for GFP
expression at the C-terminus. (B) Live cell confocal images of HEK
cells after transfection with the indicated constructs showed that
the full-length protein and each of the three serial truncation
constructs were expressed in the cytoplasm and did not form
cellular aggregates. The cells were incubated with TMRE (red) to
identify mitochondria, and nuclei were label with Hoechst (blue).
Found at: doi:10.1371/journal.pone.0013823.s007 (3.35 MB TIF)
Figure S7 Western blot for protein expression for the HKIII
constructs. (A) Western blot of cell lysates from HEK293 cells
overexpressing the indicated constructs. For each construct, 1.5 mg
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mine 2000 as described.
Found at: doi:10.1371/journal.pone.0013823.s008 (1.33 MB TIF)
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